Ex vivo expanded autologous human corneal epithelial cells containing stem cells (Chiesi)

N/A

Report date: 2022/03/01 18:07:07

Base Information

Drug NameEx vivo expanded autologous human corneal epithelial cells containing stem cells (Chiesi)

Drug Alias Name体外扩增角膜干细胞Holoclar

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Somatic cell > Corneal epithelium cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Limbal stem cell therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsHypospadiasCorneal Diseases

Global Approved IndicationsCorneal Diseases

Approved Indications in ChinaN/A

Original Approved Country/TerritoryEU

Original Approved Date2015/02/17

Country/TerritoryItalyEU

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesChiesi Farmaceutici SPA

China Registration ClassN/A

Develop Information

Active CompaniesHolostem Terapie Avanzate Srl

Inactive CompaniesN/A

Active IndicationsCorneal Diseases

Inactive IndicationsHypospadias

Other Information

ATC CodeS01XA19